IP Library Granted Patent US 8,921,355
Granted Patent B2
US 8,921,355 · App. 13/000,583 · Granted Dec 30, 2014

Macrocyclic indole derivatives useful as hepatitis C virus inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,921,355
App. No.
13/000,583
Granted
Dec 30, 2014
Kind
B2
Abstract

Inhibitors of HCV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R 1 , R 2 , R 4 , R 5 , R 6 and R 7 have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.

Claims (34)

1. A compound of Formula (I)

or a stereochemically isomeric form, N-oxide, salt, hydrate, or solvate thereof, wherein:

R 1 is a bivalent chain selected from

each R 3 is independently selected from the group comprising hydrogen, C 1-4 -alkyl and C 3-5 cycloalkyl;

a is 3, 4, 5 or 6;

each b is independently 1 or 2;

c is 1 or 2;

macrocycle A has 14 to 18 member atoms;

each R 2 is independently hydrogen, halo or C 1-4 -alkoxy;

R 4 and R 5 are hydrogen or R 4 and R 5 together form a double bond or a methylene group to form a fused cyclopropyl;

R 6 is hydrogen or methyl; and

R 7 is a C 3-7 cycloalkyl optionally substituted with halo.

2. The compound of claim 1 wherein,

R 1 is selected from —N(R 3 )—(CH 2 ) 4 —N(R 3 )—,

and,

each R 3 is independently selected from hydrogen and methyl.

3. The compound of claim 1 wherein R 2 is positioned the benzene group in para with respect to the bond linking this benzene to the indole group.

4. The compound of claim 1 wherein R 2 is selected from fluoro and methoxy.

5. The compound of claim 1 wherein R 7 is selected from cyclohexyl and 2-fluorocyclohexyl.

6. The compound of claim 1 wherein R 4 and R 5 together form a double bond.

7. The compound of claim 1 having the stereochemical configuration as illustrated by formula (IA)

8. The compound of claim 1 , selected from the group consisting of:

9. A pharmaceutical composition comprising a carrier, and as active ingredient an anti-virally effective amount of the compound of claim 1 .

10. The pharmaceutical composition of claim 9 , further comprising at least one other anti-HCV compound.

11. The pharmaceutical composition of claim 9 , further comprising at least one anti HIV compound.

12. The compound of claim 1 , which is

or a stereochemically isomeric form, N-oxide, salt, hydrate, or solvate thereof.

13. A pharmaceutical composition comprising a carrier, and as active ingredient an anti-virally effective amount of the compound of claim 12 .

14. The pharmaceutical composition of claim 13 , further comprising at least one other anti-HCV compound.

15. The pharmaceutical composition of claim 13 , further comprising at least one HIV compound.

16. The compound of claim 12 , which is

or a salt thereof.

17. The compound of claim 16 , which is

18. The compound of claim 1 , wherein macrocycle A has 17 or 18 member atoms.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2015
From: JANSSEN R & D IRELAND
To: JANSSEN SCIENCES IRELAND UC
Reel/Frame 035496/0382 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2013
From: SANDRINE M.H. VENDEVILLE; PIERRE J.M.B. RABOISSON; TSE-I LIN; ABDELLAH TAHRI; KATIE I.E. AMSSOMS
To: TIBOTEC BVBA
Reel/Frame 031142/0331 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2013
From: TIBOTEC BVBA
To: TIBOTEC PHARMACEUTICALS
Reel/Frame 031142/0518 →
CHANGE OF NAME Recorded Sep 5, 2013
From: TIBOTEC PHARMACEUTICALS
To: JANSSEN R&D IRELAND
Reel/Frame 031142/0684 →